826 related articles for article (PubMed ID: 11483329)
21. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
[TBL] [Abstract][Full Text] [Related]
22. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.
King SC; Acker JC; Kussin PS; Marks LB; Weeks KJ; Leopold KA
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):593-9. PubMed ID: 8948343
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results.
Graham MV; Pajak TE; Herskovic AM; Emami B; Perez CA
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):819-25. PubMed ID: 7860394
[TBL] [Abstract][Full Text] [Related]
24. A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.
Cagney DN; Thirion PG; Dunne MT; Fleming C; Fitzpatrick D; O'Shea CM; Finn MA; O'Sullivan S; Booth C; Collins CD; Buckney SJ; Shannon A; Armstrong JG
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):30-38. PubMed ID: 29097074
[TBL] [Abstract][Full Text] [Related]
25. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
26. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT; Zhang Q; Rosenthal DI; List M; Axelrod R; Sherman E; Weber R; Nguyen-Tân PF; El-Naggar A; Konski A; Galvin J; Schwartz D; Trotti A; Silverman C; Singh A; Godette K; Bonner JA; Jones CU; Garden AS; Shenouda G; Matthiesen C; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):687-699. PubMed ID: 27727066
[TBL] [Abstract][Full Text] [Related]
27. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
LoRusso PM; Herbst RS; Rischin D; Ranson M; Calvert H; Raymond E; Kieback D; Kaye S; Gianni L; Harris A; Bjork T; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Feyereislova A; Heyes A; Averbuch SD; Ochs J; Baselga J
Clin Cancer Res; 2003 Jun; 9(6):2040-8. PubMed ID: 12796366
[TBL] [Abstract][Full Text] [Related]
28. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
[TBL] [Abstract][Full Text] [Related]
29. Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Abdel-Wahab M; Abitbol A; Lewin A; Troner M; Hamilton K; Markoe A
Am J Clin Oncol; 2005 Aug; 28(4):359-66. PubMed ID: 16062077
[TBL] [Abstract][Full Text] [Related]
30. Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy.
Bütof R; Löck S; Soliman M; Haase R; Perrin R; Richter C; Appold S; Krause M; Baumann M
Radiother Oncol; 2020 Feb; 143():44-50. PubMed ID: 31767470
[TBL] [Abstract][Full Text] [Related]
31. Accelerated fractionation in inoperable non-small cell lung cancer. A phase I/II study.
Yu E; Souhami L; Guerra J; Clark B; Gingras C; Fava P
Cancer; 1993 May; 71(9):2727-31. PubMed ID: 8385565
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
33. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
[TBL] [Abstract][Full Text] [Related]
34. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.
Jain S; Poon I; Soliman H; Keller B; Kim A; Lochray F; Yeung L; Cheung P
Radiother Oncol; 2013 Aug; 108(2):320-5. PubMed ID: 23993401
[TBL] [Abstract][Full Text] [Related]
35. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
36. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.
Saunders M; Dische S; Barrett A; Harvey A; Gibson D; Parmar M
Lancet; 1997 Jul; 350(9072):161-5. PubMed ID: 9250182
[TBL] [Abstract][Full Text] [Related]
37. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04).
Bradley JD; Scott CB; Paris KJ; Demas WF; Machtay M; Komaki R; Movsas B; Rubin P; Sause WT
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1173-9. PubMed ID: 11955727
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
39. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026
[TBL] [Abstract][Full Text] [Related]
40. An accelerated radiotherapy scheme using a concomitant boost technique for the treatment of unresectable stage III non-small cell lung cancer.
Izmirli M; Yaman F; Buyukpolat MY; Yoney A; Unsal M
Jpn J Clin Oncol; 2005 May; 35(5):239-44. PubMed ID: 15886271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
